Your browser is no longer supported. Please, upgrade your browser.
Settings
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.10% Shs Outstand161.57M Perf Week6.37%
Market Cap704.52M Forward P/E- EPS next Y-0.83 Insider Trans44.38% Shs Float161.13M Perf Month-8.66%
Income-116.40M PEG- EPS next Q-0.25 Inst Own76.90% Short Float20.82% Perf Quarter3.08%
Sales49.20M P/S14.32 EPS this Y4.00% Inst Trans9.22% Short Ratio4.90 Perf Half Y114.44%
Book/sh0.47 P/B8.53 EPS next Y10.80% ROA-75.50% Target Price- Perf Year38.28%
Cash/sh1.08 P/C3.72 EPS next 5Y19.90% ROE-603.60% 52W Range1.38 - 6.29 Perf YTD16.23%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-84.10% 52W High-36.21% Beta2.60
Dividend %- Quick Ratio1.90 Sales past 5Y29.10% Gross Margin94.60% 52W Low190.58% ATR0.25
Employees140 Current Ratio2.00 Sales Q/Q107.10% Oper. Margin- RSI (14)48.12 Volatility4.87% 6.25%
OptionableYes Debt/Eq1.05 EPS Q/Q29.90% Profit Margin- Rel Volume1.40 Prev Close3.99
ShortableYes LT Debt/Eq0.41 EarningsAug 06 BMO Payout- Avg Volume6.85M Price4.01
Recom2.10 SMA202.09% SMA50-6.94% SMA20010.82% Volume9,615,989 Change0.50%
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Sep-08-20 07:00AM  
Sep-03-20 04:15PM  
07:00AM  
Aug-31-20 09:29AM  
07:00AM  
Aug-17-20 11:41AM  
Aug-13-20 01:48PM  
Aug-11-20 08:54AM  
Aug-06-20 09:55AM  
07:00AM  
Aug-04-20 07:00AM  
Aug-03-20 11:19AM  
07:00AM  
Jul-23-20 07:00AM  
Jul-18-20 07:16PM  
Jul-15-20 11:35AM  
Jul-07-20 02:43PM  
11:57AM  
11:30AM  
Jul-02-20 07:00AM  
Jun-18-20 08:53AM  
Jun-15-20 07:43AM  
Jun-10-20 02:00PM  
Jun-09-20 04:15PM  
Jun-08-20 03:40PM  
Jun-06-20 03:01AM  
03:00AM  
Jun-02-20 07:15AM  
Jun-01-20 04:01PM  
May-28-20 04:15PM  
May-27-20 11:35PM  
06:21PM  
04:01PM  
May-26-20 07:00AM  
12:36AM  
May-19-20 03:18PM  
May-18-20 02:47PM  
09:30AM  
09:21AM  
May-15-20 07:53AM  
07:00AM  
May-13-20 11:30AM  
May-11-20 02:45PM  
May-07-20 01:07PM  
07:00AM  
May-06-20 07:31PM  
08:55AM  
07:42AM  
07:00AM  
May-05-20 07:00AM  
May-04-20 04:15PM  
Apr-29-20 01:17PM  
01:06PM  
12:34PM  
Apr-27-20 05:50PM  
11:30AM  
Apr-26-20 07:51AM  
Apr-22-20 07:00AM  
06:16AM  
Apr-21-20 12:19PM  
Apr-20-20 09:06AM  
Apr-15-20 09:36AM  
Apr-14-20 06:29PM  
02:32PM  
Apr-13-20 12:27PM  
09:54AM  
Apr-10-20 02:06PM  
Apr-09-20 05:52PM  
04:45PM  
Apr-08-20 07:00AM  
Apr-03-20 06:04PM  
07:07AM  
07:00AM  
Apr-02-20 12:28PM  
07:00AM  
Apr-01-20 08:18AM  
Mar-30-20 07:00AM  
Mar-17-20 06:41AM  
Mar-16-20 07:10AM  
Mar-13-20 02:30PM  
07:12AM  
Mar-10-20 12:00PM  
09:53AM  
Mar-09-20 08:03AM  
07:41AM  
Mar-05-20 08:25AM  
07:05AM  
07:00AM  
Mar-03-20 07:00AM  
Mar-02-20 04:15PM  
Feb-28-20 09:30AM  
Feb-27-20 12:30PM  
07:00AM  
Feb-25-20 03:25PM  
07:00AM  
Feb-20-20 07:00AM  
Feb-18-20 07:00AM  
Feb-10-20 06:25AM  
Feb-06-20 07:00AM  
Feb-05-20 11:52AM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doyle AnthonyChief Financial OfficerAug 11Buy4.0854,000220,32054,000Aug 12 04:31 PM
Stonehouse Jon PPresident & CEONov 18Buy1.4550,00072,500778,086Nov 18 04:17 PM
Sniecinski MeganChief Business OfficerNov 18Buy1.4545,00065,25045,000Nov 18 04:16 PM
LEE KENNETH B JRDirectorNov 18Buy1.455,0007,25015,252Nov 18 04:14 PM
INGRAM ROBERT ALEXANDERDirectorNov 18Buy1.4520,00029,00048,088Nov 18 04:12 PM
Hutson Nancy JDirectorNov 18Buy1.4510,00014,50053,046Nov 18 04:10 PM
HEGGIE THERESADirectorNov 18Buy1.455,0007,2506,672Nov 18 04:08 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 18Buy1.4520,00029,000102,061Nov 18 04:05 PM
Babu Yarlagadda SSenior VP - Drug DiscoveryNov 18Buy1.4525,00036,250155,587Nov 18 04:03 PM
ASELAGE STEVEDirectorNov 18Buy1.4515,00021,75021,672Nov 18 04:01 PM
AZN AstraZeneca PLC daily Stock Chart
AZN [NYSE]
AstraZeneca PLC
Index- P/E69.01 EPS (ttm)0.82 Insider Own0.50% Shs Outstand2.62B Perf Week5.06%
Market Cap147.13B Forward P/E22.02 EPS next Y2.56 Insider Trans0.00% Shs Float2.60B Perf Month0.39%
Income2.15B PEG3.58 EPS next Q0.51 Inst Own17.60% Short Float0.16% Perf Quarter6.47%
Sales25.70B P/S5.73 EPS this Y-39.70% Inst Trans-3.57% Short Ratio0.62 Perf Half Y43.20%
Book/sh4.66 P/B12.11 EPS next Y30.77% ROA3.60% Target Price59.10 Perf Year26.54%
Cash/sh2.35 P/C24.06 EPS next 5Y19.30% ROE17.80% 52W Range36.15 - 64.94 Perf YTD13.22%
Dividend1.40 P/FCF- EPS past 5Y1.00% ROI8.30% 52W High-13.07% Beta0.52
Dividend %2.48% Quick Ratio0.60 Sales past 5Y-1.70% Gross Margin80.30% 52W Low56.15% ATR1.15
Employees70600 Current Ratio0.80 Sales Q/Q7.80% Oper. Margin14.90% RSI (14)55.66 Volatility1.46% 1.76%
OptionableYes Debt/Eq1.61 EPS Q/Q481.10% Profit Margin8.40% Rel Volume0.44 Prev Close55.94
ShortableYes LT Debt/Eq1.28 EarningsJul 30 BMO Payout0.00% Avg Volume6.65M Price56.45
Recom1.60 SMA202.14% SMA501.08% SMA20010.55% Volume2,927,886 Change0.91%
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-20-20 12:30PM  
08:23AM  
06:09AM  
Sep-19-20 06:28PM  
01:04PM  
08:55AM  
06:15AM  
Sep-18-20 04:44PM  
03:57PM  
03:27PM  
03:12PM  
02:50PM  
02:36PM  
01:58PM  
01:05PM  
12:47PM  
12:11PM  
11:12AM  
09:51AM  
09:36AM  
09:26AM  
08:58AM  
08:00AM  
06:08AM  
Sep-17-20 05:48PM  
05:02PM  
04:54PM  
04:16PM  
03:55PM  
03:29PM  
11:06AM  
Sep-16-20 09:49PM  
04:43PM  
03:54PM  
02:04PM  
01:45PM  
08:33AM  
08:26AM  
02:24AM  
Sep-15-20 10:44PM  
10:43PM  
09:57PM  
09:01PM  
03:49PM  
03:24PM  
01:56PM  
01:11PM  
11:44AM  
11:10AM  
10:32AM  
05:40AM  
02:03AM  
12:15AM  
Sep-14-20 11:17PM  
10:46PM  
09:05PM  
04:34PM  
04:27PM  
04:15PM  
04:04PM  
04:00PM  
03:47PM  
03:41PM  
03:38PM  
03:16PM  
02:15PM  
01:09PM  
12:48PM  
12:48PM  
11:59AM  
11:58AM  
11:19AM  
10:22AM  
10:20AM  
09:40AM  
08:51AM  
08:47AM  
07:30AM  
07:00AM  
06:49AM  
06:45AM  
06:25AM  
04:42AM  
04:34AM  
03:15AM  
03:02AM  
02:25AM  
Sep-13-20 10:44PM  
10:39PM  
08:36PM  
08:32PM  
06:17PM  
02:43PM  
09:04AM  
04:09AM  
Sep-12-20 02:39PM  
10:56AM  
09:45AM  
06:53AM  
Sep-11-20 06:10PM  
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 07Buy19.00425,0008,075,00014,650,334Oct 09 04:53 PM
DVAX Dynavax Technologies Corporation daily Stock Chart
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-1.60 Insider Own0.10% Shs Outstand109.51M Perf Week8.38%
Market Cap617.61M Forward P/E- EPS next Y-0.65 Insider Trans- Shs Float97.74M Perf Month-16.33%
Income-137.70M PEG- EPS next Q-0.20 Inst Own74.10% Short Float17.57% Perf Quarter-16.91%
Sales34.70M P/S17.80 EPS this Y15.10% Inst Trans21.58% Short Ratio2.87 Perf Half Y89.86%
Book/sh0.60 P/B9.05 EPS next Y42.00% ROA-47.10% Target Price- Perf Year23.41%
Cash/sh1.76 P/C3.08 EPS next 5Y- ROE-468.40% 52W Range1.80 - 12.44 Perf YTD-5.07%
Dividend- P/FCF- EPS past 5Y8.90% ROI-72.10% 52W High-56.35% Beta0.93
Dividend %- Quick Ratio4.00 Sales past 5Y26.10% Gross Margin51.90% 52W Low201.67% ATR0.53
Employees231 Current Ratio5.00 Sales Q/Q-67.50% Oper. Margin- RSI (14)39.10 Volatility9.67% 9.18%
OptionableYes Debt/Eq3.08 EPS Q/Q19.30% Profit Margin- Rel Volume2.07 Prev Close5.64
ShortableNo LT Debt/Eq3.08 EarningsAug 06 AMC Payout- Avg Volume5.98M Price5.43
Recom1.70 SMA20-3.72% SMA50-26.84% SMA200-5.34% Volume12,357,845 Change-3.72%
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Sep-15-20 08:58AM  
Sep-14-20 09:53AM  
01:00AM  
Sep-08-20 03:14PM  
Sep-07-20 11:08AM  
Sep-05-20 08:02AM  
Aug-31-20 04:10PM  
Aug-13-20 08:00AM  
Aug-12-20 12:12PM  
10:07AM  
Aug-11-20 11:27AM  
09:14AM  
Aug-10-20 08:38AM  
Aug-06-20 08:20PM  
04:02PM  
Aug-05-20 11:56AM  
Aug-03-20 03:53PM  
08:00AM  
Jul-30-20 04:05PM  
Jul-29-20 12:33PM  
Jul-28-20 08:19AM  
Jul-27-20 10:53AM  
Jul-23-20 05:50PM  
08:00AM  
Jul-21-20 04:10PM  
04:10PM  
Jul-17-20 11:42AM  
11:23AM  
05:29AM  
Jul-16-20 10:02AM  
08:40AM  
Jul-14-20 11:28AM  
08:00AM  
08:00AM  
Jul-13-20 05:45PM  
Jul-10-20 04:01PM  
Jul-08-20 10:09AM  
08:30AM  
Jul-07-20 09:43AM  
08:23AM  
Jul-05-20 09:16AM  
Jun-30-20 11:30AM  
09:45AM  
Jun-22-20 11:28AM  
09:06AM  
09:00AM  
Jun-21-20 11:15PM  
Jun-19-20 07:41AM  
06:00AM  
03:38AM  
Jun-15-20 11:45AM  
Jun-10-20 09:30AM  
Jun-09-20 08:00AM  
Jun-04-20 06:37PM  
Jun-01-20 04:00PM  
May-30-20 05:12PM  
May-29-20 04:29PM  
08:53AM  
May-28-20 04:05PM  
May-27-20 04:05PM  
May-22-20 10:19AM  
May-21-20 09:00PM  
04:01PM  
May-20-20 01:18PM  
May-19-20 04:08PM  
09:00AM  
07:16AM  
May-14-20 09:24AM  
May-09-20 02:31PM  
May-07-20 04:10PM  
Apr-30-20 12:33PM  
Apr-28-20 04:10PM  
Apr-23-20 04:10PM  
01:44PM  
Apr-20-20 08:15AM  
Apr-17-20 08:44AM  
07:15AM  
Apr-16-20 07:30AM  
Apr-15-20 08:26AM  
Apr-13-20 06:12AM  
Apr-08-20 08:00AM  
Apr-02-20 04:30PM  
Apr-01-20 07:32AM  
Mar-26-20 11:56AM  
10:09AM  
07:30AM  
Mar-24-20 08:30AM  
Mar-13-20 07:38AM  
Mar-11-20 06:05PM  
04:47PM  
04:10PM  
02:30PM  
Mar-04-20 12:30PM  
Mar-02-20 08:00AM  
Feb-28-20 07:55AM  
Feb-24-20 04:05PM  
Feb-18-20 04:05PM  
Feb-05-20 02:45PM  
Dec-17-19 07:56AM  
Dec-16-19 04:15PM  
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janssen RobertSenior Vice PresidentJul 17Sale11.0950,000554,500127,266Jul 20 07:42 PM
Hack Andrew A. F.DirectorMay 27Buy5.001,000,0005,000,0008,525,000May 28 05:13 PM
Janssen RobertSenior Vice PresidentMay 19Sale6.3315,00094,950177,266May 19 07:05 PM
Janssen RobertSenior Vice PresidentMay 06Sale4.5228,000126,560192,266May 07 06:37 PM
Janssen RobertSenior Vice PresidentMay 05Sale4.439,00039,870220,266May 07 06:37 PM
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E11.38 EPS (ttm)3.45 Insider Own0.20% Shs Outstand2.49B Perf Week0.38%
Market Cap98.93B Forward P/E12.93 EPS next Y3.04 Insider Trans0.00% Shs Float2.48B Perf Month-3.63%
Income8.66B PEG3.16 EPS next Q0.87 Inst Own11.90% Short Float0.40% Perf Quarter-4.48%
Sales45.40B P/S2.18 EPS this Y31.60% Inst Trans-4.80% Short Ratio3.61 Perf Half Y17.76%
Book/sh7.09 P/B5.54 EPS next Y1.00% ROA8.00% Target Price48.67 Perf Year-4.99%
Cash/sh4.25 P/C9.24 EPS next 5Y3.60% ROE53.60% 52W Range31.43 - 48.25 Perf YTD-16.45%
Dividend1.89 P/FCF16.79 EPS past 5Y10.30% ROI14.30% 52W High-18.63% Beta0.63
Dividend %4.81% Quick Ratio0.70 Sales past 5Y8.00% Gross Margin68.00% 52W Low24.91% ATR0.65
Employees99437 Current Ratio1.00 Sales Q/Q-2.40% Oper. Margin25.50% RSI (14)44.89 Volatility1.03% 1.34%
OptionableYes Debt/Eq2.33 EPS Q/Q133.30% Profit Margin19.10% Rel Volume1.33 Prev Close39.47
ShortableYes LT Debt/Eq1.89 Earnings- Payout10.90% Avg Volume2.76M Price39.26
Recom2.00 SMA20-0.67% SMA50-2.81% SMA200-6.33% Volume3,682,575 Change-0.53%
Feb-12-20Downgrade Shore Capital Hold → Sell
Jan-16-20Downgrade Barclays Equal Weight → Underweight
Dec-02-19Initiated SVB Leerink Outperform
Nov-21-19Upgrade UBS Neutral → Buy
Oct-11-19Upgrade Cantor Fitzgerald Hold → Buy
Sep-03-19Upgrade Societe Generale Sell → Buy
Sep-03-19Resumed Citigroup Neutral
Aug-13-19Resumed JP Morgan Neutral
Jun-17-19Resumed Morgan Stanley Underweight
Mar-08-19Downgrade Shore Capital Buy → Hold
Feb-22-19Downgrade UBS Buy → Neutral
Jan-14-19Downgrade Exane BNP Paribas Outperform → Neutral
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Aug-30-18Downgrade Liberum Buy → Hold
Apr-04-18Upgrade Exane BNP Paribas Neutral → Outperform
Mar-22-18Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-09-18Upgrade Kepler Reduce → Hold
Nov-06-17Downgrade Investec Buy → Hold
Oct-26-17Downgrade BofA/Merrill Buy → Neutral
Sep-18-20 05:50PM  
03:57PM  
12:11PM  
11:12AM  
05:27AM  
Sep-17-20 05:48PM  
05:02PM  
04:54PM  
Sep-16-20 02:04PM  
10:33AM  
07:33AM  
Sep-15-20 04:23PM  
01:56PM  
06:30AM  
Sep-14-20 04:39PM  
07:00AM  
Sep-13-20 02:43PM  
Sep-11-20 11:47AM  
10:19AM  
10:00AM  
09:14AM  
Sep-10-20 11:06AM  
07:20AM  
05:15AM  
Sep-09-20 06:45PM  
06:33PM  
11:50AM  
10:17AM  
09:18AM  
09:00AM  
Sep-08-20 04:39PM  
01:58PM  
12:45PM  
12:05PM  
11:39AM  
10:39AM  
10:33AM  
09:11AM  
06:44AM  
06:30AM  
06:30AM  
Sep-04-20 09:25AM  
07:15AM  
Sep-03-20 04:12PM  
03:31PM  
03:14PM  
03:12PM  
12:57PM  
12:46PM  
10:17AM  
09:41AM  
09:37AM  
09:19AM  
07:59AM  
07:55AM  
07:00AM  
05:26AM  
03:02AM  
01:00AM  
Sep-01-20 06:57PM  
06:05PM  
09:39AM  
09:09AM  
08:32AM  
Aug-31-20 04:30PM  
03:39PM  
03:17PM  
03:11PM  
12:45PM  
09:54AM  
08:50AM  
08:04AM  
08:00AM  
08:00AM  
Aug-28-20 10:42PM  
01:51PM  
11:52AM  
07:59AM  
Aug-27-20 05:12PM  
12:23PM  
07:07AM  
Aug-26-20 02:41PM  
03:54AM  
Aug-24-20 08:30AM  
Aug-21-20 11:50AM  
Aug-20-20 01:50PM  
11:21AM  
Aug-19-20 04:48PM  
Aug-17-20 10:38AM  
07:00AM  
Aug-16-20 07:54PM  
10:19AM  
Aug-15-20 07:11AM  
Aug-14-20 02:43PM  
12:00PM  
02:10AM  
Aug-13-20 05:19PM  
04:03PM  
01:52PM  
07:00AM  
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLCDirectorJul 21Buy18.00361,1116,499,9982,248,304Jul 22 04:18 PM
GLAXOSMITHKLINE PLCFormer 10% OwnerOct 18Buy28.00357,1429,999,9762,982,855Oct 22 05:36 PM
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
INO [NASD]
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own1.40% Shs Outstand167.52M Perf Week68.65%
Market Cap2.62B Forward P/E28.10 EPS next Y0.61 Insider Trans-9.24% Shs Float164.19M Perf Month17.48%
Income-222.00M PEG- EPS next Q-0.19 Inst Own34.20% Short Float31.56% Perf Quarter19.13%
Sales2.70M P/S972.21 EPS this Y-15.40% Inst Trans40.48% Short Ratio1.52 Perf Half Y135.46%
Book/sh1.20 P/B14.17 EPS next Y140.80% ROA-82.40% Target Price19.00 Perf Year599.59%
Cash/sh2.41 P/C7.06 EPS next 5Y0.00% ROE-217.80% 52W Range1.91 - 33.79 Perf YTD415.15%
Dividend- P/FCF- EPS past 5Y-14.60% ROI-137.90% 52W High-49.69% Beta0.86
Dividend %- Quick Ratio10.10 Sales past 5Y-17.00% Gross Margin- 52W Low787.73% ATR1.95
Employees190 Current Ratio10.10 Sales Q/Q200.00% Oper. Margin- RSI (14)57.41 Volatility23.20% 13.34%
OptionableYes Debt/Eq0.43 EPS Q/Q-175.70% Profit Margin- Rel Volume1.76 Prev Close15.67
ShortableYes LT Debt/Eq0.43 EarningsAug 10 AMC Payout- Avg Volume33.99M Price17.00
Recom2.90 SMA2040.09% SMA50-2.01% SMA20054.75% Volume59,772,116 Change8.49%
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Sep-18-20 02:50PM  
12:47PM  
11:49AM  
Sep-17-20 05:35PM  
10:36AM  
Sep-16-20 04:20PM  
02:04PM  
11:32AM  
10:29AM  
Sep-15-20 06:04PM  
11:31AM  
06:11AM  
Sep-14-20 12:25PM  
06:45AM  
Sep-10-20 03:10PM  
10:02AM  
Sep-09-20 06:20PM  
11:43AM  
08:03AM  
07:08AM  
Sep-08-20 04:25PM  
03:29PM  
09:46AM  
09:36AM  
08:27AM  
08:00AM  
Sep-04-20 10:53AM  
Sep-03-20 03:29PM  
07:50AM  
06:10AM  
Sep-02-20 05:23PM  
01:34PM  
06:37AM  
Sep-01-20 03:39PM  
08:00AM  
Aug-28-20 01:51PM  
12:03PM  
07:59AM  
Aug-27-20 10:32AM  
06:08AM  
Aug-26-20 07:34AM  
Aug-24-20 11:14AM  
Aug-23-20 06:12AM  
Aug-21-20 01:46PM  
11:31AM  
Aug-19-20 06:09AM  
Aug-16-20 09:10AM  
07:07AM  
Aug-15-20 08:14AM  
07:02AM  
Aug-14-20 10:55AM  
Aug-13-20 06:42PM  
12:42PM  
08:33AM  
07:32AM  
05:04AM  
Aug-12-20 12:07PM  
11:30AM  
Aug-11-20 04:47PM  
04:42PM  
03:17PM  
01:21PM  
11:27AM  
08:58AM  
08:20AM  
07:35AM  
04:49AM  
02:30AM  
12:00AM  
Aug-10-20 10:52PM  
05:17PM  
04:05PM  
Aug-07-20 11:01AM  
Aug-05-20 06:41AM  
Aug-04-20 06:46AM  
Aug-02-20 11:00AM  
Jul-31-20 10:54AM  
08:48AM  
06:00AM  
Jul-30-20 11:25AM  
08:34AM  
08:00AM  
Jul-29-20 10:33AM  
09:13AM  
07:30AM  
Jul-28-20 07:02AM  
05:51AM  
Jul-27-20 08:00AM  
Jul-26-20 02:33PM  
Jul-25-20 08:08AM  
01:21AM  
Jul-24-20 12:16PM  
08:49AM  
06:46AM  
Jul-23-20 09:00AM  
Jul-20-20 05:23PM  
Jul-18-20 09:34AM  
06:32AM  
Jul-17-20 04:23PM  
01:07PM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Humeau LaurentChief Scientific OfficerAug 10Sale19.0619,467371,00443,966Aug 12 06:59 PM
Kim Jong JosephChief Executive OfficerJul 30Sale21.13100,0002,113,4501,188,313Jul 31 07:12 PM
KIES PETERCFOJul 15Option Exercise2.4035,00084,000154,290Jul 17 07:00 PM
KIES PETERCFOJul 15Sale24.9535,000873,208119,290Jul 17 07:00 PM
KIES PETERCFOJun 30Sale26.5035,000927,500119,290Jul 02 09:05 PM
Humeau LaurentChief Scientific OfficerJun 22Sale14.7019,467286,16563,433Jun 24 04:56 PM
BENITO SIMON XDirectorMay 20Option Exercise4.608,75040,25060,400May 20 05:37 PM
BENITO SIMON XDirectorMay 20Sale15.958,750139,59451,650May 20 05:37 PM
Weiner David B.DirectorMay 11Sale11.842,40428,463827,219May 12 04:26 PM
Weiner David B.DirectorMar 12Sale11.143,50038,990821,610Mar 12 04:40 PM
Weiner David B.DirectorMar 10Sale9.323,50032,620825,110Mar 12 04:40 PM
Weiner David B.DirectorMar 09Sale18.003,50063,000816,944Mar 09 04:20 PM
Kim Jong JosephChief Executive OfficerJan 13Buy3.1122,50069,9751,100,707Jan 13 12:10 PM
NVAX Novavax, Inc. daily Stock Chart
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own0.70% Shs Outstand58.62M Perf Week13.53%
Market Cap7.08B Forward P/E4.98 EPS next Y21.75 Insider Trans-29.54% Shs Float55.24M Perf Month-26.32%
Income-93.30M PEG- EPS next Q1.83 Inst Own53.00% Short Float15.35% Perf Quarter67.35%
Sales50.20M P/S141.00 EPS this Y44.90% Inst Trans123.03% Short Ratio1.06 Perf Half Y946.96%
Book/sh3.15 P/B34.40 EPS next Y139.45% ROA-23.30% Target Price- Perf Year1505.33%
Cash/sh7.69 P/C14.09 EPS next 5Y0.00% ROE173.30% 52W Range3.54 - 189.40 Perf YTD2622.61%
Dividend- P/FCF221.19 EPS past 5Y5.60% ROI- 52W High-42.79% Beta1.35
Dividend %- Quick Ratio3.00 Sales past 5Y-9.50% Gross Margin- 52W Low2961.02% ATR13.00
Employees165 Current Ratio3.00 Sales Q/Q944.10% Oper. Margin- RSI (14)46.07 Volatility11.57% 11.21%
OptionableYes Debt/Eq1.74 EPS Q/Q82.30% Profit Margin- Rel Volume0.73 Prev Close115.51
ShortableYes LT Debt/Eq1.74 EarningsAug 10 AMC Payout- Avg Volume7.98M Price108.36
Recom2.70 SMA20-0.28% SMA50-15.05% SMA200120.28% Volume5,802,359 Change-6.19%
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Sep-20-20 08:23AM  
Sep-19-20 08:55AM  
Sep-18-20 04:44PM  
03:23PM  
03:12PM  
02:50PM  
02:36PM  
12:47PM  
11:56AM  
09:26AM  
Sep-17-20 05:02PM  
04:54PM  
07:26AM  
Sep-16-20 02:04PM  
12:50PM  
Sep-15-20 06:06PM  
04:27PM  
03:49PM  
03:41PM  
02:06PM  
11:58AM  
11:10AM  
07:55AM  
07:25AM  
07:00AM  
06:04AM  
Sep-14-20 04:27PM  
11:58AM  
Sep-13-20 05:10AM  
Sep-11-20 11:51AM  
Sep-10-20 04:19PM  
07:00AM  
06:50AM  
06:12AM  
Sep-09-20 06:20PM  
04:13PM  
01:57PM  
11:30AM  
09:17AM  
06:45AM  
Sep-08-20 04:39PM  
04:29PM  
04:15PM  
03:14PM  
01:52PM  
11:39AM  
08:54AM  
06:30AM  
Sep-06-20 06:11AM  
Sep-05-20 07:46AM  
Sep-04-20 05:04PM  
01:51PM  
12:01PM  
11:20AM  
Sep-03-20 07:01PM  
04:15PM  
04:12PM  
03:31PM  
02:50PM  
01:59PM  
01:03PM  
12:47PM  
10:44AM  
09:57AM  
09:35AM  
09:19AM  
08:24AM  
07:55AM  
07:50AM  
Sep-02-20 06:31PM  
05:14PM  
11:48AM  
06:37AM  
02:09AM  
Sep-01-20 05:41PM  
11:34AM  
11:21AM  
Aug-31-20 04:10PM  
12:45PM  
12:28PM  
10:28AM  
10:00AM  
08:55AM  
08:21AM  
07:44AM  
Aug-30-20 12:41PM  
09:22AM  
Aug-29-20 08:08AM  
07:13AM  
Aug-28-20 01:51PM  
12:03PM  
08:31AM  
08:16AM  
07:59AM  
06:08AM  
Aug-27-20 06:09PM  
04:16PM  
03:44PM  
03:26PM  
01:30PM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM
Glenn Gregory MPresident, R&DJan 31Buy3.861,2504,8251,373Feb 04 05:11 PM
MCMANUS MICHAEL A JRDirectorNov 18Sale3.823,92915,0159,951Nov 20 04:17 PM
QDEL Quidel Corporation daily Stock Chart
QDEL [NASD]
Quidel Corporation
Index- P/E53.00 EPS (ttm)3.57 Insider Own8.90% Shs Outstand42.12M Perf Week17.45%
Market Cap7.16B Forward P/E12.12 EPS next Y15.63 Insider Trans-5.00% Shs Float36.99M Perf Month-21.47%
Income154.70M PEG7.36 EPS next Q4.06 Inst Own89.90% Short Float5.60% Perf Quarter-10.02%
Sales655.10M P/S10.93 EPS this Y-0.50% Inst Trans0.95% Short Ratio1.52 Perf Half Y112.97%
Book/sh14.52 P/B13.04 EPS next Y30.30% ROA16.60% Target Price264.75 Perf Year195.89%
Cash/sh1.92 P/C98.67 EPS next 5Y7.20% ROE26.80% 52W Range55.25 - 306.72 Perf YTD152.31%
Dividend- P/FCF47.00 EPS past 5Y59.90% ROI15.20% 52W High-38.28% Beta0.97
Dividend %- Quick Ratio1.10 Sales past 5Y23.80% Gross Margin66.30% 52W Low242.64% ATR15.21
Employees1250 Current Ratio1.60 Sales Q/Q86.30% Oper. Margin29.20% RSI (14)49.59 Volatility7.56% 8.91%
OptionableYes Debt/Eq0.02 EPS Q/Q5226.90% Profit Margin23.60% Rel Volume1.75 Prev Close170.75
ShortableYes LT Debt/Eq0.00 EarningsJul 30 AMC Payout0.00% Avg Volume1.36M Price189.31
Recom2.50 SMA205.15% SMA50-16.46% SMA20031.46% Volume2,383,144 Change10.87%
May-12-20Downgrade JP Morgan Neutral → Underweight $120 → $158
Mar-26-20Downgrade Barclays Overweight → Equal Weight $90
Oct-23-18Resumed Raymond James Strong Buy $80
Mar-08-18Upgrade Raymond James Outperform → Strong Buy
Jan-22-18Reiterated Barclays Overweight $50 → $60
Jan-04-18Upgrade CL King Neutral → Buy
Sep-19-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
Mar-03-11Downgrade Wedbush Outperform → Neutral $14 → $13
Sep-17-20 07:19AM  
07:00AM  
Sep-14-20 11:34PM  
05:50PM  
09:41AM  
Sep-11-20 12:09PM  
Sep-08-20 03:58PM  
03:53PM  
Sep-07-20 05:10AM  
Sep-04-20 11:30AM  
Sep-01-20 02:20PM  
Aug-31-20 12:33PM  
Aug-29-20 09:09AM  
Aug-28-20 10:17AM  
08:31AM  
Aug-27-20 05:07PM  
04:10PM  
03:39PM  
02:46PM  
02:32PM  
10:04AM  
Aug-26-20 03:03PM  
Aug-25-20 11:00AM  
Aug-23-20 09:00AM  
Aug-22-20 07:12AM  
Aug-20-20 02:30PM  
Aug-19-20 09:30PM  
11:30AM  
Aug-18-20 05:48AM  
Aug-14-20 07:16AM  
Aug-13-20 12:48PM  
Aug-12-20 06:00PM  
Aug-10-20 06:38PM  
11:13AM  
Aug-06-20 04:21PM  
10:58AM  
Aug-04-20 09:24AM  
Aug-03-20 11:30AM  
07:12AM  
Aug-02-20 10:51AM  
09:07AM  
Jul-31-20 11:30AM  
11:00AM  
Jul-30-20 08:30PM  
04:10PM  
Jul-29-20 06:00PM  
Jul-24-20 05:45PM  
09:22AM  
Jul-23-20 12:33PM  
Jul-22-20 11:00AM  
05:30AM  
Jul-19-20 07:10AM  
Jul-18-20 08:26PM  
08:44AM  
Jul-17-20 11:00PM  
04:23PM  
06:37AM  
Jul-16-20 05:45PM  
03:04PM  
Jul-13-20 06:10PM  
Jul-10-20 05:45PM  
12:45PM  
Jul-09-20 10:00AM  
Jul-07-20 10:55PM  
08:17AM  
Jul-06-20 05:00PM  
09:41AM  
07:00AM  
Jul-04-20 04:25PM  
Jul-02-20 11:30AM  
Jun-29-20 08:40AM  
08:22AM  
Jun-26-20 12:29PM  
05:47AM  
Jun-24-20 12:07PM  
07:03AM  
Jun-23-20 08:20AM  
07:11AM  
Jun-19-20 01:15AM  
Jun-18-20 12:45PM  
09:26AM  
Jun-16-20 12:03PM  
Jun-15-20 11:30AM  
10:42AM  
07:23AM  
Jun-12-20 06:18PM  
03:45PM  
Jun-11-20 06:49PM  
11:30AM  
Jun-09-20 07:00PM  
Jun-08-20 10:19AM  
06:58AM  
Jun-05-20 10:00AM  
Jun-02-20 12:45PM  
Jun-01-20 02:34PM  
09:50AM  
May-29-20 10:34AM  
08:33AM  
07:50AM  
May-28-20 07:53AM  
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Strobeck MatthewDirectorSep 03Buy155.6340062,25438,145Sep 04 07:09 PM
Strobeck MatthewDirectorSep 02Buy166.657,3001,216,51137,745Sep 04 07:09 PM
BRYANT DOUGLAS CPresident & CEOAug 31Buy174.995,000874,965455,823Sep 01 06:05 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Option Exercise34.142,58288,1439,216Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Sale250.002,582645,5006,634Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Option Exercise35.875,610201,21512,244Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Sale250.005,6101,402,5006,634Aug 24 12:03 PM
BRYANT DOUGLAS CPresident & CEOAug 11Buy234.125,0001,170,600450,823Aug 11 08:38 PM
BUECHLER KENNETH FDirectorAug 03Option Exercise14.437,800112,55467,624Aug 05 08:26 PM
STEWARD RANDALL JChief Financial OfficerAug 03Option Exercise18.4621,166390,65724,014Aug 05 08:33 PM
Michael Edward L.DirectorAug 03Buy288.123,5001,008,4046,434Aug 05 08:32 PM
Kroll WernerSVP, R&DAug 03Sale287.482,072595,6504,599Aug 05 08:28 PM
BUECHLER KENNETH FDirectorAug 03Sale289.227,8002,255,94659,824Aug 05 08:26 PM
STEWARD RANDALL JChief Financial OfficerAug 03Sale286.3121,1666,060,1262,848Aug 05 08:33 PM
BRYANT DOUGLAS CPresident & CEOJun 11Buy160.335,000801,670445,823Jun 12 05:53 PM
Kroll WernerSVP, R&DMay 27Option Exercise0.004,37608,975May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Option Exercise20.4668,1521,394,42272,751May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Sale174.4468,15211,888,1494,599May 27 07:54 PM
Bujarski Robert JosephSVP, NA Comm Ops & Gen CounselMay 20Sale189.4120,0003,788,28213,383May 22 07:59 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Option Exercise17.9515,970286,67515,432May 20 08:02 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Option Exercise31.8816,332520,69927,171May 20 08:07 PM
STEWARD RANDALL JChief Financial OfficerMay 18Sale185.3520,0003,707,0402,848May 20 08:11 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Sale192.8228,3125,459,113524May 20 08:07 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Sale198.4615,9703,169,3876,634May 20 08:02 PM
BUECHLER KENNETH FDirectorMay 15Option Exercise0.001,842059,824May 18 08:06 PM
SLACIK CHARLES PDirectorMay 15Option Exercise0.00549011,352May 18 08:16 PM
SLACIK CHARLES PDirectorMay 14Option Exercise0.002,100010,803May 18 08:16 PM
SCHULER JACK WDirectorMay 14Option Exercise0.002,10003,103,249May 18 08:14 PM
POLAN MARY LAKE PH DDirectorMay 14Option Exercise0.002,100022,884May 18 08:12 PM
ORDONEZ KATHYDirectorMay 14Option Exercise0.001,85601,856May 18 08:10 PM
Michael Edward L.DirectorMay 14Option Exercise0.002,10002,934May 18 08:08 PM
BUECHLER KENNETH FDirectorMay 14Option Exercise0.002,100057,982May 18 08:06 PM
WIDDER KENNETH JDirectorMay 14Option Exercise0.002,100014,416May 18 08:21 PM
Strobeck MatthewDirectorMay 14Option Exercise0.002,10007,399May 18 08:19 PM
POLAN MARY LAKE PH DDirectorMay 11Sale204.276,7001,368,63020,784May 12 08:01 PM
BUECHLER KENNETH FDirectorMay 11Sale200.005,0001,000,00055,882May 13 08:01 PM
BUECHLER KENNETH FDirectorMay 05Option Exercise13.2510,449138,44960,882May 07 08:05 PM
Russell Edward KeithSVP, Business DevelopmentFeb 26Option Exercise15.4012,601194,05529,791Feb 28 08:03 PM
Russell Edward KeithSVP, Business DevelopmentFeb 26Sale79.5812,6011,002,79617,190Feb 28 08:03 PM
POLAN MARY LAKE PH DDirectorJan 07Option Exercise21.079,041190,49428,584Jan 09 08:23 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 06Option Exercise15.6711,122174,22620,426Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 06Sale70.0011,122778,5409,304Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 05Option Exercise23.414,700110,02714,004Dec 09 07:59 PM
BORKAR RATAN SSVP, Intl Comm OperationsDec 05Sale70.004,700329,0009,304Dec 09 07:59 PM
Kroll WernerSVP, R&DDec 03Option Exercise22.856,620151,26723,389Dec 05 09:35 PM
Kroll WernerSVP, R&DDec 03Sale68.0222,9511,561,0783,795Dec 05 09:35 PM
Russell Edward KeithSVP, Business DevelopmentNov 26Option Exercise19.5615,974312,43832,452Nov 27 07:47 PM
Russell Edward KeithSVP, Business DevelopmentNov 26Sale68.7315,9741,097,95116,478Nov 27 07:47 PM
BORKAR RATAN SSVP, Intl Comm OperationsNov 26Sale68.406,621452,8859,304Nov 27 07:45 PM
BORKAR RATAN SSVP, Intl Comm OperationsNov 25Sale69.1833222,96915,925Nov 27 07:45 PM
BRYANT DOUGLAS CPresident & CEONov 20Option Exercise22.42377,7448,470,451679,186Nov 22 08:03 PM
STEWARD RANDALL JChief Financial OfficerSep 23Option Exercise15.4029,328451,65148,787Sep 25 07:59 PM
STEWARD RANDALL JChief Financial OfficerSep 23Sale62.6029,3281,836,04119,459Sep 25 07:59 PM